Research and application of alkaloid compound in prevention and treatment of abdominal aortic aneurysm
By using colchicine to inhibit the expression of vascular smooth muscle cells and matrix metalloproteinase, the lack of drugs in the prior art for the prevention and treatment of abdominal aortic aneurysms is solved, and effective improvement and vascular protection of abdominal aortic aneurysms are achieved.
Patent Information
- Application Number
- CN202411288415.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There are no clear indications in the prior art for the prevention and treatment of abdominal aortic aneurysms. It is urgent to explore the finding of new therapeutic drugs and prevention and treatment targets.
Colchicine is used as an alkaloid compound to improve the pathological damage of abdominal aortic aneurysms in mice by inhibiting the infiltration of inflammatory cells in the vascular membrane, inhibiting the transformation of vascular smooth muscle cells into synthesis and expression of matrix metalloproteinase.
Colchicine significantly reduces the inflammatory response and oxidative stress levels of blood vessel walls, slows down aortic dilation, and provides new intervention strategies and research and development ideas for the prevention and treatment of abdominal aortic aneurysms.
Smart Images

Figure CN119074707A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to the research and application of an alkaloid compound in preventing and treating abdominal aortic aneurysm. Background Art
[0002] Abdominal aortic aneurysm (AAA) is an aortic dilatation disease in which the diameter of the aorta is irreversibly dilated due to a variety of reasons, exceeding the normal diameter by more than 50%. In the human body, when the diameter of the aorta (especially the diameter of the aorta segment below the renal artery branch) is greater than 3 cm, AAA can be considered to occur. AAA is one of the vascular degenerative diseases with the highest risk in vascular surgery. AAA has an insidious onset. As the aorta continues to dilate and the aneurysm continues to grow, the risk of rupture is also gradually increasing; once ruptured, its mortality rate is as high as 80%. Statins, angiotensin-converting enzyme inhibitors, and angiotensin II receptor antagonists can delay the progression of AAA to a certain extent, but their exact efficacy remains to be determined. So far, there is no drug with a clear indication for AAA. Finding new targets for the prevention and treatment of AAA and new therapeutic drugs urgently requires in-depth exploration and research.
[0003] Colchicine is a neutral lipophilic tricyclic alkaloid extracted from the seeds and bulbs of the lily family plant Colchicum. It was first crudely extracted by Pelletier and Caventou in 1820. In 1955, Corrodi and Hardegger revealed the chemical structure of colchicine, broadening its clinical application. The U.S. Food and Drug Administration (FDA) has approved colchicine for the treatment of familial Mediterranean fever, gout, arthritis, and biliary cirrhosis. Colchicine mainly exerts anti-inflammatory and immunosuppressive effects by inhibiting the function of neutrophils and macrophages; at the same time, it inhibits cell mitosis by blocking microtubule formation and exerting anti-fibrosis effects. In 2023, the FDA issued an announcement: Colchicine 0.5mg tablets can be used to treat patients with existing atherosclerotic diseases or adults with multiple cardiovascular risk factors. At the same time, a study in the European Journal of Preventive Cardiology also showed that the use of low doses of colchicine can benefit patients who have received antihypertensive and lipid-lowering drugs.
[0004] Studies have found that hypertension and hyperlipidemia are important risk factors for AAA and tumor rupture. However, there are no reports on the use of colchicine in the treatment of AAA. Summary of the invention
[0005] 1. Technical problems to be solved The purpose of the present invention is to solve the problem that there is no colchicine for treating AAA in the prior art, and to propose research and application of an alkaloid compound in preventing and treating abdominal aortic aneurysm.
[0006] 2. Technical solution In order to achieve the above object, the present invention adopts the following technical solutions: An alkaloid compound, wherein the alkaloid compound is colchicine.
[0007] The present invention also proposes an alkaloid compound for use in improving pathological damage of abdominal aortic aneurysm.
[0008] The invention also proposes an alkaloid compound for use in preventing and treating abdominal aortic aneurysm.
[0009] The invention also proposes an alkaloid compound for use in preparing a drug for preventing and treating abdominal aortic aneurysm.
[0010] The present invention also proposes a research method for the use of alkaloid compounds in the prevention and treatment of abdominal aortic aneurysm, comprising the following steps: Step 1: First, establish the mouse AAA model by incubating with porcine trypsin PPE and administering fumaric acid aminopropionitrile BAPN in drinking water to induce abdominal aortic aneurysm in mice; Step 2: While the AAA model was being established in mice, 0.1 mg / kg colchicine was intraperitoneally injected into the mice. Colchicine was administered to the mice simultaneously with the AAA model, once a day, for 2 consecutive weeks. Step 3: After 2 weeks, the abdominal aorta of the mice was isolated, and the degree of aortic dilatation and damage were evaluated by HE / EVG / Masson staining of the blood vessels. The specific method was to use a biological microscope to remove the adhesion tissue around the aorta, and to measure the maximum aortic diameter by electronic vernier caliper combined with HE staining and Image software; Step 4: Finally, the abdominal aorta tissue of mice was detected to explore the possible molecular mechanism by which colchicine improves AAA injury in mice.
[0011] Preferably, the mouse AAA mold making body in step 1 comprises the following steps: S1: After the mouse was anesthetized with 1% sodium pentobarbital solution (40 mg / kg), it was fixed on a foam board with its abdomen facing upwards; the mouse abdomen and surrounding areas were disinfected with 75% alcohol, and the mouse abdominal skin was gently cut open with sterilized scissors and forceps, and the abdomen was opened layer by layer; the small intestine, large intestine, etc. were gently pulled out with a cotton swab and placed on a gauze strip soaked in saline; the mouse abdominal aorta was gently freed with a cotton swab and forceps, especially the aortic segment above the iliac artery and below the renal artery branch; S2: Soak the cotton strips cut in advance in the PPE solution, and then wrap them on the free aortic tissue; the incubation time is 40 minutes, during which about 5 μl of PPE solution can be added every 10 minutes; S3: After the incubation time is over, remove the cotton strips, use a cotton swab dipped in saline and gently wipe three times; close the abdomen layer by layer, suture the mouse, and return it to the animal room after it wakes up; S4: The mice were given 0.4% BAPN drinking water. The normal control group was a group incubated with normal saline in the abdominal aorta of mice and given drinking water without BAPN. All mice were free to drink water and eat, and move or rest freely in the cage.
[0012] Preferably, in step 4, the expression of VSMCs phenotype-related proteins and MMPs is detected by Western blot, the changes in the levels of inflammatory factors and oxidative stress in the vascular wall are analyzed by immunofluorescence staining, and the infiltration of inflammatory cells in the adventitia of the vascular wall is detected by flow cytometry.
[0013] 3. Beneficial effects Compared with the prior art, the advantages of the present invention are: 1. In the present invention, colchicine with a clear anti-inflammatory effect is proposed for the first time, which can improve AAA damage in mice by inhibiting the infiltration of inflammatory cells in the adventitia of the vascular wall, inhibiting the transformation of vascular smooth muscle cells to synthetic type and the expression of matrix metalloproteinases, etc., which helps to reveal the new use of colchicine, a commonly used clinical drug, and provides a new intervention strategy and research and development idea for the prevention and treatment of abdominal aortic aneurysm; 2. In the present invention, it is demonstrated that low doses of colchicine can improve AAA pathological damage in mice by inhibiting the transformation of vascular smooth muscle cells (VSMCs) to synthetic type and the expression of matrix metalloproteinases (MMPs), reducing vascular wall inflammatory response and oxidative stress levels, etc.; and further studies have found that colchicine may play a vascular protective role by inhibiting the infiltration of inflammatory cells in the vascular adventitia. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The AAA model in mice was successfully established by using PPE+BAPN as proposed in the present invention; Figure 2 This is a graph showing the experimental results that colchicine proposed in the present invention can slow down aortic dilatation in a mouse AAA model; Figure 3 This is a diagram showing the experimental results that colchicine proposed in the present invention can inhibit the transformation of VSMCs to synthetic type and the expression of MMPs; Figure 4 This is a graph showing the experimental results that colchicine proposed in the present invention can reduce the levels of inflammation and oxidative stress in AAA blood vessel walls; Figure 5 This is a graph showing the experimental results that the colchicine proposed in the present invention can reduce the infiltration of inflammatory cells in the adventitia of the vascular wall. DETAILED DESCRIPTION
[0015] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments.
[0016] Embodiment 1: An alkaloid compound, wherein the alkaloid compound is colchicine.
[0017] In this embodiment, a research method for alkaloid compounds in preventing and treating abdominal aortic aneurysm comprises the following steps: Step 1: First, establish the mouse AAA model by incubating with porcine trypsin PPE and administering fumaric acid aminopropionitrile BAPN in drinking water to induce abdominal aortic aneurysm in mice; Step 2: While the AAA model was being established in mice, 0.1 mg / kg colchicine was intraperitoneally injected into the mice. Colchicine was administered to the mice simultaneously with the AAA model, once a day, for 2 consecutive weeks. Step 3: After 2 weeks, the abdominal aorta of the mice was isolated, and the degree of aortic dilatation and damage were evaluated by HE / EVG / Masson staining of the blood vessels. The specific method was to use a biological microscope to remove the adhesion tissue around the aorta, and to measure the maximum aortic diameter by electronic vernier caliper combined with HE staining and Image software; Step 4: Finally, the abdominal aorta tissue of mice was detected to explore the possible molecular mechanism by which colchicine improves AAA injury in mice.
[0018] In this example, colchicine, which has a clear anti-inflammatory effect, is proposed for the first time. It can improve AAA injury in mice by inhibiting the infiltration of inflammatory cells in the adventitia of the vascular wall, inhibiting the transformation of vascular smooth muscle cells to the synthetic type and the expression of matrix metalloproteinases, etc., which helps to reveal the new use of colchicine, a commonly used clinical drug, and provides a new intervention strategy and research and development idea for the prevention and treatment of abdominal aortic aneurysm.
[0019] Embodiment 2: The mice used in this example were C57BL / 6J mice (hereinafter referred to as C57 mice), which were purchased from Shanghai Slake Experimental Animal Co., Ltd. All animal operations involved in the experiment ensured that the mice were treated humanely.
[0020] In this example, the mouse AAA model was constructed as follows: (1) C57 mice were anesthetized with 1% sodium pentobarbital solution (40 mg / kg) and fixed on a foam board with the abdomen facing up; (2) Use 75% alcohol to disinfect the mouse abdomen and surrounding areas, and use sterilized scissors and forceps to gently cut the mouse abdominal skin and open the abdomen layer by layer; (3) Use a cotton swab to gently pull out the small intestine, large intestine, etc. and place them on a gauze strip soaked in saline; (4) Use cotton swabs and forceps to gently free the abdominal aorta of the mouse, especially the aortic segment above the iliac artery and below the renal artery branch; (5) Soak the cotton strips cut in advance in the PPE solution and then wrap them around the free aortic tissue; (6) The incubation time is 40 min, during which approximately 5 μL of PPE solution can be added every 10 min; (7) After the incubation time is over, remove the cotton strips and use a cotton swab dipped in saline to gently wipe three times; (8) Close the abdomen of the mouse layer by layer, suture it, and return it to the animal room after it wakes up; (9) The mice were given 0.4% BAPN drinking water. The normal control group was a group incubated with normal saline in the abdominal aorta of mice and given drinking water without BAPN. All mice were allowed to drink water and eat freely and move or rest freely in the cage. After 2 weeks, the samples were collected and the formation of AAA in the mice was comprehensively judged by electronic vernier calipers combined with HE staining (measured using Image software).
[0021] In this embodiment, Figure 1 As shown: After 2 weeks of PPE incubation and combined with BAPN drinking water, the abdominal aorta of mice was obviously enlarged and bulged, and the abdominal aorta was significantly dilated. Electronic vernier caliper combined with HE staining (measured by Image software) showed that the average diameter of the abdominal aorta in the model group was about 1.0 mm, and the average diameter of the abdominal aorta in the normal control group was about 0.4 mm. After conversion, it can be seen that the diameter of the abdominal aorta in the model group is more than 1.5 times the average diameter of the normal control group, indicating that we have successfully constructed a mouse AAA model using PPE+BAPN.
[0022] Embodiment 3: The mouse AAA model used in this example was obtained by inducing PPE+BAPN, and the specific process was the same as in Example 2.
[0023] In this example, colchicine (0.1 mg / kg) was administered to mice simultaneously with AAA modeling, intraperitoneally injected once a day for 2 consecutive weeks. After administration, the mice were anesthetized with pentobarbital, and the aortic tissue of the mice was obtained for subsequent experiments.
[0024] In this embodiment, after the modeling is completed, the aorta is obtained after the mouse is perfused with physiological saline under anesthesia; the adhesion tissue around the aorta is removed using a biological microscope, the maximum aortic diameter is measured by an electronic vernier caliper combined with HE staining (measured by Image software), the expression of VSMCs phenotype-related proteins and MMPs is detected by Western blot, the changes in the levels of inflammatory factors and oxidative stress in the vascular wall are analyzed by immunofluorescence staining, and the infiltration of inflammatory cells in the adventitia of the vascular wall is detected by flow cytometry.
[0025] (1) Antibodies against VSMCs phenotype-related proteins and MMPs were purchased from CST and operated according to the instructions. α-SMA is a marker for contractile VSMCs, OPN is a marker for synthetic VSMCs, and MMP2 and MMP9 are two MMPs with significantly increased expression in AAA disease. (2) Antibodies against inflammatory factor-related proteins TNF-α / IL-1β / IL-8 were purchased from Abcam, and antibodies against oxidative stress-related proteins NOX2 / NOX4 were purchased from Santa Cruz. The stronger the immunofluorescence, the higher the expression level of the protein.
[0026] (3) Antibodies used for multicolor flow cytometry sorting: CD45 antibody, CD11b antibody, F4 / 80 antibody, CD86 antibody, and CD163 antibody were purchased from Affnity.
[0027] In this embodiment, Figure 2 Colchicine can significantly slow down the dilatation of the abdominal aorta in AAA; Figure 3 As shown: Colchicine can inhibit the transformation of VSMCs from contractile to synthetic type in the aorta tissue of AAA mice, and inhibit the expression of MMP2 and MMP9; In this embodiment, Figure 4 Colchicine can reduce the production of inflammatory factors and oxidative stress in the diseased aorta tissue of AAA mice. Figure 5 Colchicine can reduce the infiltration of inflammatory cells in the adventitia around the aortic tissue of AAA mice. These results indicate that colchicine can improve AAA injury and play a vascular protective role.
[0028] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. An alkaloid compound, It is characterized in that The alkaloid compound is colchicine.
2. An alkaloid compound according to claim 1, It is characterized in that Application in improving pathological damage of abdominal aortic aneurysm.
3. An alkaloid compound according to claim 1, It is characterized in that Application in the prevention and treatment of abdominal aortic aneurysm.
4. An alkaloid compound according to claim 1, It is characterized in that Application in the preparation of drugs for the prevention and treatment of abdominal aortic aneurysm.
5. The research method of an alkaloid compound in preventing and treating abdominal aortic aneurysm according to claim 1, It is characterized in that The following steps are involved: Step 1: First, establish the mouse AAA model by incubating with porcine trypsin PPE and administering fumaric acid aminopropionitrile BAPN in drinking water to induce abdominal aortic aneurysm in mice; Step 2: While the AAA model was being established in mice, 0.1 mg / kg colchicine was intraperitoneally injected into the mice. Colchicine was administered to the mice simultaneously with the AAA model, once a day, for 2 consecutive weeks. Step 3: After 2 weeks, the abdominal aorta of the mice was isolated, and the degree of aortic dilatation and damage were evaluated by HE / EVG / Masson staining of the blood vessels. The specific method was to use a biological microscope to remove the adhesion tissue around the aorta, and to measure the maximum aortic diameter by electronic vernier caliper combined with HE staining and Image software; Step 4: Finally, the abdominal aorta tissue of mice was detected to explore the possible molecular mechanism by which colchicine improves AAA injury in mice.
6. The research method of an alkaloid compound in preventing and treating abdominal aortic aneurysm according to claim 5, It is characterized in that In step 1, the mouse AAA model is made The following steps are involved: S1: After the mouse was anesthetized with 1% sodium pentobarbital solution (40 mg / kg), it was fixed on a foam board with its abdomen facing upwards; the mouse abdomen and surrounding areas were disinfected with 75% alcohol, and the mouse abdominal skin was gently cut open with sterilized scissors and forceps, and the abdomen was opened layer by layer; the small intestine, large intestine, etc. were gently pulled out with a cotton swab and placed on a gauze strip soaked in saline; the mouse abdominal aorta was gently freed with a cotton swab and forceps, especially the aortic segment above the iliac artery and below the renal artery branch; S2: Soak the cotton strips cut in advance in the PPE solution, and then wrap them on the free aortic tissue; the incubation time is 40 minutes, during which about 5 μl of PPE solution can be added every 10 minutes; S3: After the incubation time is over, remove the cotton strips, use a cotton swab dipped in saline and gently wipe three times; close the abdomen layer by layer, suture the mouse, and return it to the animal room after it wakes up; S4: The mice were given 0.4% BAPN drinking water. The normal control group was a group incubated with normal saline in the abdominal aorta of mice and given drinking water without BAPN. All mice were free to drink water and eat, and move or rest freely in the cage.
7. The research method of an alkaloid compound in preventing and treating abdominal aortic aneurysm according to claim 5, It is characterized in that In step 4, the expression of VSMCs phenotype-related proteins and MMPs is detected by Western blot, the changes in the levels of inflammatory factors and oxidative stress in the vascular wall are analyzed by immunofluorescence staining, and the infiltration of inflammatory cells in the adventitia of the vascular wall is detected by flow cytometry.
